Double-blind, placebo-controlled trial of mifepristone on cognition and depression in alcohol dependence.

ABSTRACT:

Background

Alcohol dependence is a significant issue contributing to disease burden. Changes in cortisol concentrations during alcohol withdrawal are associated with cognitive deficits and symptoms of depression. Current treatments are only successful for a small proportion of people and do not target cognitive deficits and symptoms of depression experienced by those who are alcohol dependent. The aim of this research is to determine the potential efficacy of mifepristone, a type II glucocorticoid receptor antagonist, to prevent symptoms of depression and cognitive deficits following alcohol detoxification.

Methods

This was a phase 2 therapeutic use trial. It was a double-blind randomised controlled clinical trial of mifepristone versus inactive placebo treatment. The trial

SUBMITTER: Donoghue K 

PROVIDER: S-EPMC7493392 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature